Creating an animal model of tendinopathy by inducing chondrogenic differentiation with kartogenin by Yuan, T et al.
RESEARCH ARTICLE
Creating an Animal Model of Tendinopathy
by Inducing Chondrogenic Differentiation
with Kartogenin
Ting Yuan1,2, Jianying Zhang1, Guangyi Zhao1, Yiqin Zhou1, Chang-Qing Zhang2, James
H-C. Wang1*
1 MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of
Medicine, Pittsburgh, PA, United States of America, 2 Department of Orthopaedic Surgery, Shanghai Sixth
People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
*wanghc@pitt.edu
Abstract
Previous animal studies have shown that long term rat treadmill running induces over-use
tendinopathy, which manifests as proteoglycan accumulation and chondrocytes-like cells
within the affected tendons. Creating this animal model of tendinopathy by long term tread-
mill running is however time-consuming, costly and may vary among animals. In this study,
we used a new approach to develop an animal model of tendinopathy using kartogenin
(KGN), a bio-compound that can stimulate endogenous stem/progenitor cells to differentiate
into chondrocytes. KGN-beads were fabricated and implanted into rat Achilles tendons.
Five weeks after implantation, chondrocytes and proteoglycan accumulation were found at
the KGN implanted site. Vascularity as well as disorganization in collagen fibers were also
present in the same site along with increased expression of the chondrocyte specific
marker, collagen type II (Col. II). In vitro studies confirmed that KGN was released continu-
ously from KGN-alginate in vivo beads and induced chondrogenic differentiation of tendon
stem/progenitor cells (TSCs) suggesting that chondrogenesis after KGN-bead implantation
into the rat tendons is likely due to the aberrant differentiation of TSCs into chondrocytes.
Taken together, our results showed that KGN-alginate beads can be used to create a rat
model of tendinopathy, which, at least in part, reproduces the features of over-use tendino-
pathy model created by long term treadmill running. This model is mechanistic (stem cell dif-
ferentiation), highly reproducible and precise in creating localized tendinopathic lesions. It is
expected that this model will be useful to evaluate the effects of various topical treatments
such as NSAIDs and platelet-rich plasma (PRP) for the treatment of tendinopathy.
Introduction
Tendinopathy is a prevalent tendon disorder that affects a large proportion of people in both
athletic and occupational settings involving repetitive motion. Patients with tendinopathy
often experience a number of debilitating symptoms including pain, stiffness or tenderness,
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edema and swelling in the injured tendon area [1]. However, the current treatment options for
tendinopathy are largely palliative because the mechanisms causing the tendon disorder are
not well understood [2].
Typically, tendinopathy is studied using samples from patients who choose surgical inter-
ventions to alleviate tendinopathy symptoms [3–6]. While much of our understating of tendi-
nopathy stems from the histological analysis of the tendon samples removed during surgery,
variations in the etiology of the disease in each patient has made it difficult to devise an effec-
tive treatment modality for the tendon disease. Thus, animal models of tendinopathy are
required to investigate the cellular and molecular mechanisms regulating the tendon disorder
to devise effective treatment protocols. Moreover, to develop better treatment options for ten-
dinopathy, it is essential to have a reproducible, cost-effective animal model of tendinopathy
that will allow evaluation of the tendon disease progression and enable development of better
treatment options.
However, it is challenging to develop a single model that exhibits all features of tendinopa-
thy, which is now considered to be a spectrum of tendon disorders resulting from multiple etio-
logic factors [7]. Common methods used to create animal tendinopathy models are treadmill
running and biochemical injections [8,9].
Treadmill running was the preferred method to create tendinopathy models because
mechanical loading is considered to be a major etiologic factor of tendinopathy in specific
load-bearing tendons, such as patellar and Achilles tendons. Besides, this method is also "physi-
ological" in the sense that it creates tendinopathy that occurs naturally. Different treadmill run-
ning protocols (uphill, downhill, etc.) have been used to induce tendinopathic features like
disorganization and disintegration of collagen fibers [10] [11], microtearing and increase in
glycosaminoglycan content [12], and altered tendon cell morphology from elongated to round
shape in the Achilles tendons [13]. Repetitive mechanical loading also caused tendon sub-fail-
ure injury in rat patellar tendons [8]. Moreover, our recent study on over-use tendinopathy
suggested that degenerative changes in tendons may be caused by the aberrant differentiation
of tendon stem/progenitor cells (TSCs) in response to excessive mechanical loading placed on
the tendons [9].
While the mechanical loading-induced tendinopathy in animal models are physiologically
relevant, they have serious limitations because it is time-consuming and costly to create these
models. Additionally, the tendinopathic lesions induced by mechanical loading may vary
among different animals and in different tendon regions of the same animals. Therefore, it is
highly desirable to create an animal model in a more convenient, efficient and reproducible
fashion.
Injection is another commonly used method to create animal models of tendinopathy. In
the injection-induced tendinopathy model, tendon degeneration is achieved by injecting chem-
icals or bio-factors into the tendons. These include cell-activating factors (CAF) [14], prosta-
glandins [15,16], collagenase [17,18] and TGF-β1[19]. Although these injection models can
capture certain features of tendinopathy such as inflammation, disorganization of collagen
matrix and hyper-vascularity, diffusion of the injected "bio-agents" into the surrounding area
often poses a challenge to create "clean" and localized tendinopathic lesions inside tendons. For
example, PGE1 and PGE2 [15] leakage into areas around the treated region creates uninten-
tional inflammation in these regions.
Therefore in this study, our aim was to create a localized animal model of tendinopathy by
implanting fine beads of a bio-compound called kartogenin (KGN) into rat tendons. KGN is a
small heterocyclic compound that can stimulate endogenous stem/progenitor cells such as
mesenchymal stem cells to differentiate into chondrocytes in mice [20]. In tendinopathy
patients, chondrocyte-like cells have been demonstrated in the degenerated regions where
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increased glycosaminoglycan was present [5,6,21] and upregulated expression of proteogly-
cans, aggrecan and biglycan transcripts was detected [4]. Therefore, in this study we attempted
to create a tendinopathy model by implanting fine beads of alginate containing KGN into rat
tendons.
Methods
Ethics statement
The University of Pittsburgh IACUC approved all experimental protocols for the use of rats in
this study.
Preparation of KGN beads
KGN beads were prepared by dissolving 5 mg KGN in 0.3 ml DMSO to make a 50 mM KGN
stock solution, which was diluted in double distilled water to obtain a 5 mM KGN working
solution. From this, 400 μl was added to 1 ml of 2% alginate to form a 1.5 mM KGN-DMSO-
alginate suspension. The KGN-DMSO-alginate mixture was then drawn into a pipette and
squeezed to obtain drops that were allowed to fall into a 2% calcium chloride solution to stimu-
late gel formation. Each drop contained about 5 μL of KGN-DMSO-alginate and therefore
2.5 μg KGN in each bead (Fig 1A). Similarly, control beads containing only DMSO-alginate
were also prepared such that each bead contained 2.85% DMSO, which is identical to the
amount of DMSO present in each KGN bead. All beads were air dried for 48 hrs before use
(Fig 1B).
In vivo animal experiments
To determine the chondrogenic potential of KGN in vivo, we implanted KGN beads into 8–12
weeks old female Sprague Dawley (SD) rats. Twelve rats were used for this experiment and
were assigned randomly to one of two groups: KGN bead implanted group or DMSO bead
Fig 1. KGN bead implantation in rat Achilles tendons in vivo. A. KGN beads were prepared by squeezing
drops of KGN+DMSO+alginate solution through a pipet into a calcium chloride solution. B. KGN beads air
dried for 48 hrs. Diameter of the dried beads was 169 ± 32 μm. C. Rat Achilles tendon with the implanted
bead. KGN implanted rats were allowed free cage activities until further analyses. Arrow (C) points to the
KGN bead implanted site. Bar– 1 mm.
doi:10.1371/journal.pone.0148557.g001
A New Animal Model of Tendinopathy
PLOS ONE | DOI:10.1371/journal.pone.0148557 February 5, 2016 3 / 15
implanted group. After anesthetizing rats by inhaling 1–3% isoflurane, one KGN bead or
DMSO bead was implanted into a small puncture (< 0.5 mm in diameter) created in the lateral
strand of the Achilles tendons 5 mm proximal to the calcaneal insertion and sutured (Fig 1C).
Rats were allowed unrestricted activities in cages and sacrificed 5 weeks after implantation.
Their Achilles tendons were collected for gross inspection and further analyses. Note that the
amount of DMSO used in this study was too low to induce cytotoxic effects on cells. It has been
shown that low DMSO concentrations (< 10%) do not cause cytotoxic changes in enterocyte-
like cells in vitro [22].
Histochemical analyses
For histochemical analysis, Achilles tendons were harvested from the KGN and DMSO bead
implanted rats after 5 weeks and were immersed in frozen section medium (Neg 50; Richard-
Allan Scientific; Kalamazoo, MI) in pre-labeled base molds. The tendons were then flash-fro-
zen by placing in 2-methylbutane chilled in liquid nitrogen. The frozen tissue blocks were
stored at -80°C until required or used immediately. Each frozen tissue was cut into 8 μm thick
sections and placed on glass slides to dry overnight at room temperature. The sections were
then fixed in 4% paraformaldehyde for 15 min and stained with hematoxylin/eosin (H&E).
Additional tendon sections were also stained with Safranin O/fast green and Alcian blue/fast
nuclear red according to our protocols [9].
Immunofluorescence staining
To further characterize the tendinopathic lesions induced by KGN, we examined neovasculari-
zation and chondrogenesis in the KGN or DMSO bead implanted tendons by immunostaining
with anti-CD31 and anti-collagen type II antibodies. Briefly, the frozen Achilles tendons from
the KGN or DMSO beads implanted groups were cut into 8 μm thick sections and fixed in ace-
tone for 5 min at room temperature. After washing in PBS and treating with blocking one solu-
tion (Nacalai Tesque Inc. Kyoto, Japan), the tissue sections were incubated with anti-CD31
(1:300) primary antibody (Abcam, Cambridge, MA) overnight at 4°C. Then, slides were rinsed
3 times in PBS and incubated with Cy3-conjugated secondary antibody. To determine chon-
drogenesis, the tissue sections were fixed with 4% paraformaldehyde in PBS for 15 min and
incubated with mouse anti-collagen type II (1:300) primary antibody (Cat. #CP18-100UG;
Millipore, Billerica, MA) at room temperature for 2 hrs. After washing three times in PBS, sec-
tions were incubated in FITC-conjugated goat anti-mouse IgG (1:500) at room temperature for
2 hrs. Excess secondary antibodies were removed by washing in PBS, followed by staining cel-
lular nuclei with Hoechst fluorochrome 33342 (H33342). Finally, stained sections were
observed through a fluorescence microscope (Nikon eclipse microscope, TE2000-U, Nikon
Instruments Inc., Melville, NY, USA).
KGN release experiment in vitro
Twenty KGN-alginate beads obtained as above were weighed and incubated in 1 ml PBS at
37°C with continuous rotation using a micro-hybridization incubator (Robbines Scientific,
Sunnyvale, CA). Every 10 min for 70 min, the beads were separated from the solution by a vac-
uum filtration funnel, dried gently using a soft tissue paper and weighed to record bead weight.
The amount of KGN released from the beads into the PBS solution was also determined every
10 min for 70 min by obtaining an aliquot of the PBS using high performance liquid chroma-
tography (HPLC; Agilent Technologies, Santa Clara, CA) and a standard curve (R2 = 0.996).
This experiment was performed three times with 3 replicates in each treatment.
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TSC isolation and Safranin O staining
To determine whether KGN-induced chondrogenesis in rat tendons is mediated through ten-
don stem/progenitor cells (TSCs), we performed the following in vitro study. Briefly, 5 Sprague
Dawley (SD) rats (8–10 weeks old, female) were used in the experiments to obtain Achilles ten-
dons (n = 10). Then, after discarding the tendon sheath and surrounding paratenon, the ten-
dons were minced into small pieces. A 0.5 ml solution containing collagenase type I (3 mg/ml)
and dispase (4 mg/ml) was then used to digest 10 mg of the minced tendon tissue at 37°C for 1
hr. Cells from this digest were recovered by centrifugation at 1,500 g for 15 min and the cell
pellet was re-suspended and cultured in Dulbecco’s modified Eagle medium (DMEM, Lonza,
Walkersville, MD) containing 20% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg
/ml streptomycin (Atlanta Biologicals, Lawrenceville, GA) in T25 flasks. TSC colonies were
observed after about 2 weeks in culture. These colonies were sub-cultured and used for the in
vitro assays. Prior to experimentation, TSCs were characterized for the presence of stem cell
markers, nucleostemin, Oct-4 and SSEA-1, as previously described [9].
TSCs at passage 1–2 were seeded in 6-well plates at a density of 2× 105 per well and cultured
for 21 days in DMEM (Dulbecco’s modified Eagle’s medium) plus 10% fetal bovine serum
(FBS) with various concentrations of KGN (0 nM, 1 nM, 10 nM, 100 nM, 1 μM and 10 μM).
The medium was changed every 3 days and after 21 days, cells were stained with Safranin O
solution (Sigma, St. Louis, MO) as previously described [23]. The experiment was performed
three times with 3 replicates in each treatment.
qRT-PCR analysis of TSCs in vitro
Expression of chondrocyte related genes, aggrecan, collagen type II (Col. II) and Sox-9, in
TSCs treated with various KGN concentrations was determined using standard qRT-PCR pro-
tocols [23]. Rat-specific primers for the chondrocyte markers (Table 1) were adopted from pre-
vious studies and synthesized by Invitrogen (Invitrogen, Grand Island, NY). The housekeeping
gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), served as an internal control. Rel-
ative gene expression levels were estimated using the 2-ΔΔCt method [24]. The experiment was
performed three times with 3 replicates in each treatment.
Statistical analyses
One-way ANOVA was used, followed by Fisher's Least Significant Difference (LSD) test for
multiple comparisons. Differences between two groups were considered significant when P-
values were less than 0.05.
Results
Effects of KGN bead implantation on rat Achilles tendons in vivo
Towards creating an animal model of tendinopathy, we first determined the effects of KGN
bead implantation on rat Achilles tendons. Five weeks after KGN bead implantation,
Table 1. Rat RT-PCR primer sequences.
Gene Forward Reverse
GAPDH 5’-AACTCCCTCAAGATTGTCAGCA-3’ 5’-TCCACCACCCTGTTGGCTGTA-3’
Aggrecan 5’-TCAGGAACTGAACTCAGTGG-3’ 5’-GCCACTGACTTCCACAGA-3’
Collagen-II 5’-AGTGGAAGAGCGGAGACTA-3’ 5’-GACAGGCCCTATGTCCACAC-3’
SOX-9 5’-AGCGACAACTTTACCAG-3’ 5’-GGAAAACAGAGAACGAAAC-3'
doi:10.1371/journal.pone.0148557.t001
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thickening of the paratenon tissues occurred (Fig 2A); in contrast, the DMSO bead implanted
control tendons had a white glistening appearance (Fig 2B) similar to the gross appearance of
intact tendons (Fig 2C). Examination of the H&E stained tendon sections revealed typical ten-
dinopathy features such as hypercellularity and collagen disorganization only in the KGN bead
implanted tendon sections (Fig 3A and 3C). However, the DMSO bead implanted control tis-
sues appeared normal with no signs of disruption in the collagen structure or increased cellular
contents (Fig 3B and 3D). In addition, the KGN bead implanted tendons had round cells (Fig
3A and 3C) unlike the DMSO bead implanted tendons that had a more elongated cell structure
typical of normal tendon cells (Fig 3B and 3D).
Furthermore, staining for Safranin O/fast green and Alcian blue/fast nuclear red was posi-
tive only in the rat Achilles tendons that received the KGN bead implantation (Fig 4A, 4B, 4C
and 4D) but not in the DMSO bead implanted controls (Fig 4E and 4F) indicating the pres-
ence of extensive amounts of proteoglycans only in the KGN-bead implanted tendons. More
importantly, staining was observed only in the KGN bead implanted region but not in the sur-
rounding fibril tissues and other sites in the neighboring areas (arrows and triangles in A, B).
In addition, immunostaining of the KGN bead implanted areas with anti-CD31 antibody
revealed positive staining only in the KGN bead implanted areas (Fig 5A and 5B) that over-
lapped with Alcian blue and fast red staining in the region (Fig 5C). CD31 and Alcian blue pos-
itive regions were not observed in the DMSO bead implanted control tendons (Fig 5D, 5E and
5F). Immunohistochemical staining for the chondrocyte marker, Col. II, was also intense in
the KGN bead implanted rat Achilles tendons (Fig 6A and 6C) but not in the DMSO control
group (Fig 6D and 6F). These chondrocyte positive regions also showed presence of numerous
cellular nuclei (Fig 6B) when compared to DMSO control (Fig 6E). Together, these findings
indicate that KGN induces localized chondrogenesis with neo-vascularization in rat Achilles
tendons.
KGN release from KGN-alginate beads in vitro
To assess how KGN was released into the surroundings after implantation of KGN-beads into
the tendon, we performed an in vitro experiment. We found that the weight and size of alginate
Fig 2. Gross appearance of rat Achilles tendons after KGN bead implantation in vivo. Five weeks after
implantation, KGN bead implanted Achilles tendons showed thickened peritenon (A, triangle points to the
skin), while the DMSO bead implanted control Achilles tendons had an apparent normal structure (B) similar
to the normal rat Achilles tendon (C). Arrows indicate the site of KGN bead or DMSO bead implanted area.
Bar– 1 mm.
doi:10.1371/journal.pone.0148557.g002
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beads in PBS solution at 37°C increased and reached the maximum level at 40 min (Fig 7A)
likely due to absorption of PBS solution by the dry beads. However, both weight and size of the
beads started declining from 40 min and the beads completely disappeared by 70 min (Fig 7A).
Furthermore, the concentration of KGN in the PBS solution increased in a time-dependent
manner with a marginal increase in the first 20 min followed by a remarkable increase from
30–60 min after which there was a slight decline at 70 min (Fig 7B). Almost 100% of the KGN
was released from the KGN-alginate beads at 70 min thus aligning well with the complete deg-
radation of the KGN beads at this time point (Fig 7A and 7B).
Effect of KGN on chondrogenic differentiation of TSCs in vitro
To understand the cellular mechanism by which KGN induces the formation of cartilage-like
tissues in vivo, we performed in vitro experiments where TSCs from rat Achilles tendons were
treated with various concentrations of KGN. The results showed that glycosaminoglycan
matrix staining in KGN-treated TSCs increased in a KGN dose-dependent manner with the
highest accumulation in 10 μMKGN treated TSCs (Fig 8A–8F).
These results were further corroborated by qRT-PCR analysis. KGN up-regulated three
chondrocyte specific genes, aggrecan, Col. II and Sox-9 in TSCs treated with KGN in vitro.
When compared to the controls treated with DMSO (0 nM), KGN treatment significantly up-
regulated all three chondrocyte genes in a dose-dependent manner (Fig 8G). Even at the lowest
dose (1 nM) aggrecan levels increased 0.7-fold and steadily rose thereafter with increasing
KGN concentration. At the highest 100 μM concentration the expression of aggrecan reached
Fig 3. H&E staining of the KGN-bead implanted tendons. Five weeks post-implantation of KGN beads (A),
round chondrocyte-like cells (boxed) were observed in the KGN bead implanted tendons only. The boxed
area in A is enlarged in C. Green arrows indicate chondrocyte-like cells. In contrast, DMSO-bead implantation
did not affect tendon structure (B). The rectangular area in B is enlarged in D. Red arrows indicate normal
tendon cells. Bar– 100 μm.
doi:10.1371/journal.pone.0148557.g003
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the maximum level, which was 14-fold higher than the control group without KGN treatment.
However, Col. II and Sox-9 expression increased significantly only at 1 μMKGN concentration
and reached up to 2.2-fold (Col. II) and 5.7-fold (Sox-9), respectively at the highest KGN dose
(100 μM) (Fig 8G).
Discussion
Animal models of tendinopathy are essential not only to study its developmental mechanisms
but also to devise new treatment options for tendinopathy. However, the existing models using
Fig 4. Safranin O/Fast green (A, C, E) and Alcian blue/Fast nuclear red (B, D, F) staining of the KGN
bead implanted sites in rat Achilles tendons in vivo. Note that C is an enlargement of the rectangled
region in A. Arrows point to the area outside the KGN-bead implantation site that appears normal. D is an
enlargement of the yellow box in B. Triangles indicate the normal areas outside the KGN-bead implantation
site. Positive staining was observed only in the KGN bead implanted sites (A, B, C, D) indicating the presence
of glycosaminoglycan rich matrix representing chondrogenesis only at these sites. The DMSO bead
implanted tissue sections stained minimally for these stains (E, F). Bar– 100 μm.
doi:10.1371/journal.pone.0148557.g004
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long term mechanical loading on the animal tendons, typically in the form of treadmill running
are lengthy and expensive to produce, and may vary highly among animals. On the other hand,
the models created by injection of various "bio-agents" create diffused tendinopathic lesions
throughout the tendon and are not representative of real tendinopathic lesions, which are typi-
cally localized. Additionally, "bio-agents" like PGE1, PGE2, CAF and TGF-β1 [15,19,25] tend to
be unstable thus creating potential variable results. In this study, we addressed these issues and
developed a novel localized animal model of tendinopathy by implanting fine KGN-beads into
rat Achilles tendons. Our rationale to use KGN-bead implantation was to contain KGN in the
treated region and restrict its diffusion into neighboring areas. Our results showed that KGN
implantation not only resulted in the disorganization of collagen fibers, and induced hyper-cel-
lularity and vascularity at the implanted site, but also produced chondrocyte differentiation,
and increased proteoglycan accumulation and Col. II expression, which are typical features of
over-use tendinopathy created by long term treadmill running in rat supraspinatus tendons
[26,27]. Therefore, this KGN-bead implantation creates an animal model of tendinopathy sim-
ilar to that induced by treadmill running. Such KGN-induced animal tendinopathy model also
captures certain features of degenerative tendinopathy frequently observed in clinics, including
Fig 5. Immunohistochemical staining of CD31 to visualize neovascularization in KGN bead implanted rat Achilles tendons.CD31 positive staining
(red) was observed (A, B) along the Alcian blue and fast red stained regions (C) in the KGN bead implanted Achilles tendon. Rest of the tendon was negative
for CD31. Arrowheads indicate the chondrocyte-like cells and arrows point to the newly formed blood vessels. These vessels were positive for CD31. The
DMSO bead implanted tendons were negative for CD31 staining (D, E), chondrocyte-like round cells and neovascularization (F). A, B–Red indicates CD31
staining; B, E–Blue indicates nuclear staining by Hoechst 33342. C, F–Alcian blue and fast red staining. Bar– 100 μm.
doi:10.1371/journal.pone.0148557.g005
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the disorganization of collagen fibers and formation of cartilage-like tissues in tendon lesions
[28–31].
Recent studies have implicated the primary role of TSCs in the development of tendinopa-
thy [9,23,32]. TSCs are a newly discovered cell type in the tendons of mice, rats, rabbits and
humans [33–35], and growing evidence suggests their dual role in tendon homeostasis and
pathology. TSCs also play a critical role in maintaining tenocyte numbers in normal tendons
[33]. However, their role in the etiology of tendinopathy is only now emerging. In previous
studies, we established that over-use tendinopathy induced in vivo by treadmill running or in
vitro by mechanical stretching was largely caused by the aberrant differentiation of TSCs into
non-tenocytes such as chondrocytes, osteocytes and adipocytes [9]. To investigate whether
TSCs are also involved in the KGN induced tendinopathy in vivo, we performed an in vitro
study to evaluate the effects of KGN on TSC differentiation. The results indicated that KGN
can induce chondrogenic differentiation by increasing the accumulation of glycosaminoglycans
in TSCs cultured with various KGN concentrations (Fig 8). This suggests that the observed
KGN-induced chondrogenic differentiation in rat tendons in vivo (Fig 2) is likely due to the
effects of KGN on TSCs. It should be noted that during implantation of KGN-beads, a small
wound (or a small puncture) was created in the rat tendons in order to secure the KGN-bead
in place. Because of such injury, other types of stem cells, such as circulating bone marrow
Fig 6. Immunohistochemical staining of collagen type II (Col. II) in KGN bead implanted rat Achilles tendons. The KGN bead implanted site in the
Achilles tendon stained positive for Col. II (green in A, C–pink box; large boxes are enlargements of corresponding small boxes). Red arrows point to staining
artifacts (green along the tendon edge), whereas the surrounding tissues and the DMSO bead implanted tissues (D, F) stained negative for Col. II. A, D–
Green indicates positive Col. II staining; B, E–Blue indicates nuclei stained with Hoechst fluorochrome 33342; C, F–Overlay of Col. II and Hoechst staining.
Bar– 150 μm.
doi:10.1371/journal.pone.0148557.g006
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mesenchymal stem cells (BMSCs) could have migrated to the wound site and as a result, partic-
ipated in the KGN-induced chondrogenic differentiation, in addition to TSCs. Our previous
showed that KGN can also increase the chondrocyte differentiation of BMSCs [23]. Therefore,
it is likely that circulating BMSCs could have contributed to the chondrogenic differentiation
observed in vivo in rat Achilles tendons. However, because the wound was minimal and ten-
dons are not highly vascularized tissues, the contribution of these BMSCs to such chondrogenic
differentiation seen in this animal model of tendinopathy may be minimal when compared to
local TSCs. Future study is warranted to investigate the specific contributions of TSCs and
other stem cells on chondrogenesis.
Our previous study also showed that lower concentrations of KGN (1–5 μM) induced simi-
lar effects in rat TSCs [23]. These findings indicate that TSC based mechanisms in part, induce
the "features" of over-use tendinopathy in our KGN induced tendinopathy model. Therefore,
Fig 7. Release of KGN fromKGN-alginate beads during their degradation in vitro at 37°C in PBS at
various time points. (A) Changes in the weight of KGN-DMSO-alginate beads during degradation. (B) KGN
release kinetics during degradation of the KGN-DMSO-alginate beads.
doi:10.1371/journal.pone.0148557.g007
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the animal model of tendinopathy created by KGN implantation is "mechanistic," that is, it is
based on TSC’s chondrogenic differentiation, similar to conditions where TSCs are subjected
to large mechanical loading, which induces their differentiation into non-tenocyte lineages of
cells [32].
Recently, Johnson et al [20] showed that the action mechanism of KGN involved upregulat-
ing the transcription factor, Runx-1. Injection of KGN in osteoarthritic mice knees resulted in
KGN binding to filamin A, an actin-binding protein that crosslinks actin filaments [36]. This
Fig 8. Safranin O staining of KGN treated rat Achilles TSCs in vitro (A-F). TSCs treated with various KGN concentrations for 21 days were stained with
Safranin O. Red color indicates the increase in the accumulation of glycosaminoglycan-rich matrix in cell cultures in a KGN concentration-dependent manner
(KGN concentration: A– 0 nM; B– 1 nM; C– 10 nM; D– 100 nM; E– 1 μM; F– 10 μM). Gene expression analysis in KGN treated TSCs in vitro (G). Rat TSCs
were cultured in growth medium containing various KGN concentrations for 72 hrs, followed by RNA isolation and qRT-PCR to determine chondrocyte
specific gene expression. KGN up-regulated the expression of aggrecan, Col. II and Sox-9. Values represent mean ± SD. Asterisks indicate significant
differences (P < 0.05) between the KGN treated and control groups (0 nM). Bar– 100 μm.
doi:10.1371/journal.pone.0148557.g008
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binding disrupts the association between filamin A and the transcription factor, CBFβ, thus
translocating CBFβ from the cytoplasm to the nucleus that subsequently increases Runx-1,
which is normally up-regulated only in chondrocytes [20]. Thus, the increase of Runx-1 caused
by KGN is likely responsible for the appearance of more chondrocytes in our KGN-induced
tendinopathy model because Runx-1 has been shown to play a critical role in chondrogenesis
and chondrocyte proliferation [37]. Future studies will determine the effects of KGN on the sig-
naling pathways involved in rat tendons.
In this study, we used alginate gel as a carrier to deliver KGN directly into the rat Achilles
tendon. It has been reported that chondrocyte-calcium alginate gel constructs could generate
cartilage-like tissues after implantation into the subcutaneous pockets of nude mice [38].
Therefore, calcium alginate gels would be suitable delivery systems for the encapsulation and
transplantation of KGN.
Alginate forms a viscous solution when dissolved in saline and becomes a gel on contact with
divalent cations. In addition, alginate beads can preserve the viability and phenotype of chondro-
cytes [39]. This alginate-KGN bead could allow the controlled-release of KGN into the expected
location to provide an effective concentration of KGN for a prolonged time and avoid drug diffu-
sion. Indeed, our in vitro KGN release study showed that KGN is released continuously from
beads (Fig 7). These in vitro test results suggest the likelihood of KGN release after KGN-bead
implantation in vivo at the implantation site causing TSCs and possibly other types of stem cells
(e.g. BMSCs) to differentiate into chondrocytes thus forming cartilage-like tissues in the tendon.
Summary
We showed in this study that by using KGN-bead implantation, it is feasible to create an ani-
mal model of tendinopathy that exhibits localized tendinopathic lesions that are similar to
those created by long term rat treadmill running [26] and also capture certain degenerative fea-
tures of clinical tendinopathy [31]. Compared to existing tendinopathy models, this new ani-
mal model of tendinopathy has the following advantages: 1) it is cost-effective and efficient
(reduces animals and time); 2) it is highly reproducible and 3) it can create localized tendino-
pathic lesions at any region of the tendon such as insertional tendinopathy [40,41], which is
common in clinics and difficult to reproduce by other means such as treadmill running. Such a
localized tendinopathy model can be useful to study the effects of various treatments on tendi-
nopathy. For example, it can be used to evaluate the localized effects of various drugs such as
NSAIDs in the treatment of various stages of tendinopathy. Additionally, it can be used to
assess the efficacy of other treatment options, e.g. PPR, which is widely used to treat tendinopa-
thy by injection in clinics [42–44].
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